CN104208701A - Compound inhalation preparation containing antifungal drug - Google Patents
Compound inhalation preparation containing antifungal drug Download PDFInfo
- Publication number
- CN104208701A CN104208701A CN201310205736.8A CN201310205736A CN104208701A CN 104208701 A CN104208701 A CN 104208701A CN 201310205736 A CN201310205736 A CN 201310205736A CN 104208701 A CN104208701 A CN 104208701A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- antifungal
- medicine
- active component
- antifungal drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003429 antifungal agent Substances 0.000 title claims abstract description 37
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 49
- 208000006673 asthma Diseases 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 239000003862 glucocorticoid Substances 0.000 claims abstract description 9
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims abstract description 8
- 239000000812 cholinergic antagonist Substances 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 229940121375 antifungal agent Drugs 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 239000000443 aerosol Substances 0.000 claims description 17
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 14
- 229960004125 ketoconazole Drugs 0.000 claims description 14
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 13
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 13
- 108010064760 Anidulafungin Proteins 0.000 claims description 13
- 108010020326 Caspofungin Proteins 0.000 claims description 13
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 13
- 229960003942 amphotericin b Drugs 0.000 claims description 13
- 229960003348 anidulafungin Drugs 0.000 claims description 13
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 claims description 13
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 claims description 13
- 229960003034 caspofungin Drugs 0.000 claims description 13
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 13
- 229960004130 itraconazole Drugs 0.000 claims description 13
- 229960001589 posaconazole Drugs 0.000 claims description 13
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims description 13
- 229960004740 voriconazole Drugs 0.000 claims description 13
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims description 13
- 230000000843 anti-fungal effect Effects 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 229940098458 powder spray Drugs 0.000 claims description 11
- 239000000654 additive Substances 0.000 claims description 9
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
- -1 MFG Chemical compound 0.000 claims description 7
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 6
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 6
- JBRBWHCVRGURBA-UHFFFAOYSA-N broxaterol Chemical compound CC(C)(C)NCC(O)C1=CC(Br)=NO1 JBRBWHCVRGURBA-UHFFFAOYSA-N 0.000 claims description 6
- 229950008847 broxaterol Drugs 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 229960005139 epinephrine Drugs 0.000 claims description 6
- 239000003380 propellant Substances 0.000 claims description 6
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 5
- 239000000938 histamine H1 antagonist Substances 0.000 claims description 5
- 210000003630 histaminocyte Anatomy 0.000 claims description 5
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 108010049047 Echinocandins Proteins 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 150000003852 triazoles Chemical class 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 2
- IDWJWYPAJJDASX-GKXBZDASSA-N hachimycin Chemical compound O1C(=O)CC(=O)CC(O)CC(O)CCCC(O)CC(O)CC(O2)(O)CC(O)C(C(O)=O)C2CC(OC2C(C(N)C(O)C(C)O2)O)\C=C/C=C\C=C\C=C/C=C\C=C\C=C\C(C)C1C(C)CCC(O)CC(=O)C1=CC=C(N)C=C1 IDWJWYPAJJDASX-GKXBZDASSA-N 0.000 claims description 2
- 229960003372 hachimycin Drugs 0.000 claims description 2
- ALPPGSBMHVCELA-WHUUVLPESA-N methyl (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[7-(4-aminophenyl)-5-hydroxy-7-oxoheptan-2-yl]-1,3,5,7,9,13,37-heptahydroxy-18-methyl-11,15-dioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylate methyl (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-1,3,5,7,9,13,37-heptahydroxy-17-[5-hydroxy-7-[4-(methylamino)phenyl]-7-oxoheptan-2-yl]-18-methyl-11,15-dioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylate Chemical compound CC1\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C(O[C@H]2[C@H]([C@@H](N)[C@H](O)[C@@H](C)O2)O)CC(O2)C(C(=O)OC)C(O)CC2(O)CC(O)CC(O)CC(O)CC(O)CC(=O)CC(O)CC(=O)OC1C(C)CCC(O)CC(=O)C1=CC=C(N)C=C1.C1=CC(NC)=CC=C1C(=O)CC(O)CCC(C)C1C(C)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/C(O[C@H]2[C@H]([C@@H](N)[C@H](O)[C@@H](C)O2)O)CC(O2)C(C(=O)OC)C(O)CC2(O)CC(O)CC(O)CC(O)CC(O)CC(=O)CC(O)CC(=O)O1 ALPPGSBMHVCELA-WHUUVLPESA-N 0.000 claims description 2
- 229960002509 miconazole Drugs 0.000 claims description 2
- 229960000988 nystatin Drugs 0.000 claims description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 2
- 150000004291 polyenes Chemical class 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 230000001684 chronic effect Effects 0.000 abstract description 6
- 206010035664 Pneumonia Diseases 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 239000002245 particle Substances 0.000 description 22
- 239000002775 capsule Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 8
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 229960005040 miconazole nitrate Drugs 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 7
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000004177 elastic tissue Anatomy 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 3
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 3
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- OBRNDARFFFHCGE-QDSVTUBZSA-N arformoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-QDSVTUBZSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229960001271 desloratadine Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960001508 levocetirizine Drugs 0.000 description 3
- 229960003088 loratadine Drugs 0.000 description 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 229960005127 montelukast Drugs 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 2
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 2
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- ZSTCZWJCLIRCOJ-DGCLKSJQSA-N Zilpaterol Chemical compound O[C@H]1[C@H](NC(C)C)CCN2C(=O)NC3=CC=CC1=C32 ZSTCZWJCLIRCOJ-DGCLKSJQSA-N 0.000 description 2
- 229960003792 acrivastine Drugs 0.000 description 2
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229960001803 cetirizine Drugs 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960001971 ebastine Drugs 0.000 description 2
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229960000193 formoterol fumarate Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960004078 indacaterol Drugs 0.000 description 2
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229960004958 ketotifen Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 229960001144 mizolastine Drugs 0.000 description 2
- 150000002772 monosaccharides Chemical group 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229960000960 zilpaterol Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- HJPRDDKCXVCFOH-UHFFFAOYSA-N 1,3-dibutyl-7-(2-oxopropyl)purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C2=C1N(CC(C)=O)C=N2 HJPRDDKCXVCFOH-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000013606 Fungal Lung disease Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ZIJKGAXBCRWEOL-SAXBRCJISA-N Sucrose octaacetate Chemical compound CC(=O)O[C@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1 ZIJKGAXBCRWEOL-SAXBRCJISA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- 239000001344 [(2S,3S,4R,5R)-4-acetyloxy-2,5-bis(acetyloxymethyl)-2-[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxolan-3-yl] acetate Substances 0.000 description 1
- 229920006221 acetate fiber Polymers 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960004342 cetirizine hydrochloride Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229950004687 denbufylline Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001660 histamine phosphate Drugs 0.000 description 1
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- JSJCTEKTBOKRST-UHFFFAOYSA-N mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 description 1
- 229950004407 mabuterol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 125000003071 maltose group Chemical group 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001609 oxitropium bromide Drugs 0.000 description 1
- LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940013883 sucrose octaacetate Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the components and applications of a compound inhalation preparation containing an antifungal drug. When a trace amount of an antifungal drug is compounded with a drug for treating asthma and chronic obstructive pneumonia, a good curative effect will be generated; and the curative effect is more prominent, when the antifungal drug is compounded with glucocorticoid and an anti-cholinergic agent.
Description
Technical field:
The compound recipe that the present invention relates to containing antifungal drug sucks component and the purposes of preparation.
Background technology:
Antifungal drug is general designation fungus to suppression and killing action material, mainly treats fungus to mammiferous infection.The main route of administration of antifungal medicine is oral or injection, the disease that also can will be caused by atomization inspiration treatment Pulmonary Fungal Infections, but there is comparatively significantly shortcoming in this Neulized inhalation, first be that the fog produced is mainly water vapour, partial pressure of oxygen is made to reduce after diluent air, after continual ultrasonic Neulized inhalation, water vapour occupies whole respiratory tract, oxygen cannot arrive alveolar and cause patient's anoxia, next is that the fog sprayed has certain pressure, oral cavity surrounding air is stoped to enter respiratory tract, make suction gas partial pressure of oxygen lower, 3rd is asthma, Patients with Chronic Obstructive Pulmonary Disease pulmonary function is poor, and the mist low temperature of Ultrasonic atomising taring is low, small airway spasm is easily caused after suction, patient is occurred, and breast is vexed, dyspnea symptom, 4th is diameter of aspirin particle precise control after atomization, high amount of drug is at face, the site deposition such as oral mucosa, in bronchus, the target site depositions such as pulmonary are less, untoward reaction is caused to increase, drug availability is less, easy decomposition, curative effect is poor, 5th is use inconvenience, major part medicine has poor taste, patient's is suitable poor by property, so the less employing of the medicinal atomized suction of antifungal in daily treatment.
Asthma, chronic obstructive pneumonia all belong to the flow limitation disease that respiratory inflammation causes, in recent years along with the impact of smoking, air, anaphylactogen increase etc., sickness rate improves year by year, above-mentioned disease number of patients is many, mortality rate is high, social economical burden weight, has become the important public health problem affecting human health.The treatment of current treatment asthma, chronic obstructive pneumonia is mainly based on inhalant, and compound medicine is then main based on glucocorticoid, epinephrine broxaterol.Also do not find at present antifungal medicine treatment non-microorganism infect cause asthma, use in chronic obstructive pneumonia.
Summary of the invention:
The discovery that we are surprised, produces when micro-antifungal medicine forms compound recipe with the medicine for the treatment of asthma, chronic obstructive pneumonia and acts on preferably, especially more obvious containing curative effect when antifungal medicine, glucocorticoid medicine, anticholinergic agent.
We think it may is because antifungal medicine has carried out certain impact to respiratory tract cell, thus the medicine causing other treatment respiratory tract disease more easily curative effect occurs.
One can suck compound medicament composition, the pharmaceutic adjuvant of inhalation is applicable to by one or more, and as the antifungal medicine of active component, the 2-3 kind composition in the 7 class medicines such as glucocorticoid, anticholinergic agent, LTRA, mastocyte membrane stabilizer, phosphodiesterase inhibitor, epinephrine broxaterol, H1 receptor antagonist.
Described pharmaceutical composition, containing two kinds in the 7 class medicines such as glucocorticoid, anticholinergic agent, LTRA, mastocyte membrane stabilizer, phosphodiesterase inhibitor, epinephrine broxaterol, H1 receptor antagonist.
Described pharmaceutical composition, containing three kinds in glucocorticoid, anticholinergic agent, LTRA, mastocyte membrane stabilizer, phosphodiesterase inhibitor, epinephrine broxaterol, H1 receptor antagonist 7 class medicine.
Described H1 receptor antagonist is one or more in loratadine, Desloratadine, cetirizine, levocetirizine, astemizole, ketotifen, ebastine, fexofenadine, acrivastine, Primalan, mizolastine and salt thereof.Be preferably one or more in loratadine, Desloratadine, cetirizine, levocetirizine, ebastine, mizolastine, acrivastine, Primalan, ketotifen and hydrochlorate thereof, fumarate.Be more preferably one or more in loratadine, Desloratadine, cetirizine hydrochloride, levo-cetirizine hydrochloride.
Described glucocorticoid is one or more in triamcinolone acetonide, beclometasone, fluticasone, mometasone and ester, ciclesonide or budesonide.
Described anticholinergic agent is the one in ipratropium bromide, tiotropium bromide, oxitropium bromide.
Described LTRA is the one in zafirlukast, pranlukast, montelukast, tranilast.
To be set forth in mast cell membrane stabilizing agent be one in sodium cromoglicate, nedocromil.
Described phosphodiesterase inhibitor is the one in Rolipram, roflumilast, Denbufylline.
Described epinephrine broxaterol is one or more in albuterol, terbutaline, fenoterol, procaterol, formoterol, salmaterol, western sieve Bart, bambuterol, zilpaterol, Mabuterol, western Boot sieve, bromine Boot sieve, Afromoterol, QAB-149 and salt thereof.Be preferably the one in salbutamol sulfate, terbutaline sulphate, hydrochloric acid zilpaterol, formoterol fumarate, SALMETEROL XINAFOATE, maleic acid QAB-149.
Described antifungal medicine is one or more in polyenoid class, triazole type or echinocandin antifungal agent thing.
Described polyene antifungal medicine is selected from nystatin, amphotericin B, methylpartricin, hachimycin; Described antifungal drug in triazole class is selected from fluconazol, ketoconazole, miconazole, itraconazole, voriconazole, posaconazole; Described echinocandin antifungal agent thing is selected from Caspofungin, MFG, anidulafungin.
Described pharmaceutical composition, the D90 particle diameter of active component is 1 ~ 10 μm.Be preferably 1-7 μm.Be more preferably 3 ~ 6 μm.
Described pharmaceutical composition is powder spray or aerosol.Be preferably powder spray
Described pharmaceutical composition, is prepared into powder spray, and described pharmaceutic adjuvant comprises one or more in carrier, additives.
The mean diameter of described carrier is 20 ~ 80 μm, is preferably 30 ~ 40 μm.
Described carrier is one or more in saccharide, aminoacid, lecithin, phosphatidylcholine.
Described aminoacid is one or more in glycine, valine, leucine.
Described saccharide is monosaccharide, disaccharide, derived carbohydrate, monosaccharide is mannitol, fructose, glucose, described disaccharide is maltose, trehalose, cellobiose, lactose, sucrose, and described derived carbohydrate is eight acetate fiber two sugar esters, sucrose octa-acetate, eight acetic acid lactose esters, five acetic acid glucose esters, six acetic acid Nitranitols and eight acetic acid Sargassum sugar esters.Preferred lactose.Described lactose is alpha-lactose monohydrate, β-Lactis Anhydrous, one or more in amorphous spray-dried lactose, crystallizing and drying lactose, Lactis Anhydrous.Be preferably Lactis Anhydrous.
Described carrier is preferably one or both the combination in saccharide and lecithin, phosphatidylcholine.
Described additives contain one or more in surfactant, lubricant, antistatic additive.
Described surfactant is poloxamer.
Described lubricant is one or more in magnesium stearate, micropowder silica gel, Pulvis Talci.
Described powder spray, the summation of described active component and the weight ratio of carrier are 1:1 ~ 1000.Be preferably 1:1 ~ 200.
Described powder spray, becomes capsule with the form subpackage of single or multiple dosage.
Described pharmaceutical composition, is prepared into aerosol, and described pharmaceutic adjuvant comprises the pharmaceutically useful propellant and other optional additives that are applicable to aerosol.Described propellant is one or more in hydrofluoroalkane compounds.Be preferably HFA 134a (HFA134a), one or both in 1,1,1.2,3,3,3-heptafluoro-propane (HFA 227).Be more preferably HFA 134a (HFA134a).
Described aerosol, comprises solvent in additives, is selected from glycerol, propylene glycol, Polyethylene Glycol, ethanol or oleic acid.Described solvent is preferably one or more in ethanol, propylene glycol.
Described aerosol formulations is preferably, and the ethanol weight percent content as solvent is 5-20%, and the propellant of surplus.
Described pharmaceutical composition, preparation treatment non-microorganism infect cause asthma, chronic obstructive pulmonary disease medicine in application.
Described pharmaceutical composition, by glucocorticoid, anticholinergic agent, antifungal medicine as active component, and is applicable to the pharmaceutic adjuvant composition of inhalation with one or more.
The preparation method of described aerosol is: the active component micropowder adding recipe quantity in aerosol bottle, opens the valve on bottle, is imported by the mixture of the propellant of premixing and optional additives, valve-off, obtain required aerosol by valve.Optional ultra sonic bath is carried out with solubilising to aerosol bottle
Or following preparation method can be adopted: be distributed in additives by micronized active component, then add in the propellant after pre-cooling and mix, then be dispensed in aerosol bottle.
Should be appreciated that because known reason, as the retention of active component in suction apparatus, the amount of often kind of active component that patient sucks can be different from the amount of metering.Therefore the applicating ratio between active component can be different from the ratio of metering.The ratio preferably used is in the described metered proportions indicated.
Described aerosol bottle and valve system can select disclosed aerosol bottle and valve system in Chinese patent CN98805261.X.
In this patent, the dosage of said medicine is with the weighing scale of medicine itself, does not comprise the weight of its salt or ester, such as MK 100mg, in fact refers to Montelukast 100mg, instead of the sodium salt 100mg of Montelukast.
Particle diameter in the present invention is equivalent volume footpath, is the diameter of the ball identical with actual particle volume.It is generally acknowledged that the diameter that laser method is surveyed is equivalent volume footpath.
Particle diameter corresponding when D90 particle diameter refers to that the cumulative particle sizes distribution number of a sample reaches 90%.Its physical significance be particle diameter be less than it amounts of particles account for 90%, this numerical value can be detected by laser particle instrument.
Mean diameter refers to meso-position radius, can detect with laser particle analyzer.
Detailed description of the invention
Micronization of the present invention can use known mechanical crushing method or spray drying method.Mechanical crushing method refers to and utilizes the method for fluid energy mill (using Nanjing Univ. Instrument Factory QM-3A) respectively medicine and/or carrier powder to be broken into required particle diameter.Spray drying method refers to and medicine and/or carrier is dissolved in organic solvent entirely as in ethanol, through spray dryer (as Buli Minispray, 190 types, Germany or QW-500, Xishan city Lin Zhou drying machine factory), solid material is made required particle diameter.Use during spray drying method and can also add surfactant as poloxamer etc.The process conditions of spray drying method can be: inlet temperature is 105 DEG C, and outlet temperature is 68 DEG C, throughput 90%, and jet expansion internal diameter is 0.1cm, nozzle air flow velocity 800ml/min, sample introduction speed 50mL/h.
Powder spray adopts No. 3 plant capsules (sino-america joint-venture Suzhou Capsule Co., Ltd produces, trade name: Vcaps), and each embodiment feeds intake according to 1000 capsules.The capsule loading bubble-cap type of powder spray is aluminum-plastic packaged, takes out, load powder spray inhaler (Shanghai balance pharmaceutical factory) and use during use.
Medicine mist (dripping) the grain abundance measured in embodiment below detects according to the method in 2010 editions pharmacopeia annex XH.
In an embodiment, active component 2 is the combination of following medicine, and wherein μ g/ unit refers to administration unit minimum in medicine, and as Foradil Aerolizer formoterol fumarate refers to that μ g/ grain (capsule-type) or μ g/ inhale (multiple dose), aerosol refers to that μ g/ sprays.D90 particle diameter refers to that all medicines in active component 2 are as a sample, particle diameter corresponding when its cumulative particle sizes distribution number reaches 90%, its physical significance be particle diameter be less than it granule account for 90%.
Embodiment 1
According to following table, active component 1 is mixed with active component 2 with after fluid energy mill micronization, Lactis Anhydrous 10g fluid energy mill is micronized to mean diameter 42 μm, after mixing, be divided in 1000 No. 3 capsules after crossing 3 mixings of 200 mesh sieve, the active component in every capsules sees the following form.
Embodiment 2
According to following table, active component 1 is mixed with active component 2 with after fluid energy mill micronization, Lactis Anhydrous 10g fluid energy mill is micronized to mean diameter 42 μm, after mixing, is divided in 1000 No. 3 capsules after crossing 3 mixings of 200 mesh sieve,, the active component in every capsules sees the following form.
| Embodiment number | Active component 1 | Dosage (μ g/ grain) | D90 particle diameter (μm) | Active component 2 |
| 2-1 | Amphotericin B | 50 | 5.2 | M1-2 |
| 2-2 | Fluconazol | 100 | 4.9 | M1-3 |
| 2-3 | Ketoconazole | 200 | 5.8 | M1-4 |
| 2-4 | Miconazole nitrate | 200 | 5.3 | M1-5 |
| 2-5 | Itraconazole | 200 | 4.3 | M1-6 |
| 2-6 | Voriconazole | 400 | 5.1 | M1-2 |
| 2-7 | Posaconazole | 100 | 4.9 | M1-3 |
| 2-8 | Caspofungin | 200 | 5.2 | M1-4 |
| 2-9 | MFG | 500 | 4.8 | M1-5 |
| 2-10 | Anidulafungin | 100 | 5.4 | M1-6 |
| 2-11 | Amphotericin B | 50 | 5.2 | M2-2 |
| 2-12 | Fluconazol | 100 | 4.9 | M2-3 |
| 2-13 | Ketoconazole | 200 | 5.8 | M2-4 |
| 2-14 | Miconazole nitrate | 200 | 5.3 | M2-5 |
| 2-15 | Itraconazole | 200 | 4.3 | M2-6 |
| 2-16 | Voriconazole | 400 | 5.1 | M2-2 |
| 2-17 | Posaconazole | 100 | 4.9 | M2-3 |
| 2-18 | Caspofungin | 200 | 5.2 | M2-4 |
| 2-19 | MFG | 500 | 4.8 | M2-5 |
| 2-20 | Anidulafungin | 100 | 5.4 | M2-6 |
| 2-21 | Amphotericin B | 50 | 5.2 | M3-2 |
| 2-22 | Fluconazol | 100 | 4.9 | M3-3 |
| 2-23 | Ketoconazole | 200 | 5.8 | M3-4 |
| 2-24 | Miconazole nitrate | 200 | 5.3 | M3-5 |
| 2-25 | Itraconazole | 200 | 4.3 | M3-7 |
| 2-26 | Voriconazole | 400 | 5.1 | M3-2 |
| 2-27 | Posaconazole | 100 | 4.9 | M3-3 |
| 2-28 | Caspofungin | 200 | 5.2 | M3-4 |
| 2-29 | MFG | 500 | 4.8 | M3-5 |
| 2-30 | Anidulafungin | 100 | 5.4 | M3-6 |
The preparation of aerosol, active component used is the weight of 1000 administration units, and HFA-134a is HFA 134a, and HFA-227 is HFC-227ea.
Embodiment 3
Active component
Ethanol 10g
HFA-134a?490g
Preparation technology: the ethanol 1000 times of active component in following table 1 and 2 Unit Weight being added recipe quantity, stirs, divided dose fill, sealing-in dose valve system, and HFA-134a is injected in pressurization more respectively, to obtain final product.
Embodiment 4
Active component
Ethanol 10g
HFA-227?490g
Preparation technology: the ethanol 1000 times of active component in following table 1 and 2 Unit Weight being added recipe quantity, stirs, divided dose fill, sealing-in dose valve system, and HFA-227 is injected in pressurization more respectively, to obtain final product.
| Embodiment number | Active component 1 | Dosage (μ g/ sprays) | D90 particle diameter (μm) | Active component 2 |
| 4-1 | Amphotericin B | 50 | 5.2 | M1-6 |
| 4-2 | Fluconazol | 100 | 4.9 | M1-5 |
| 4-3 | Ketoconazole | 200 | 5.8 | M1-4 |
| 4-4 | Miconazole nitrate | 200 | 5.3 | M1-3 |
| 4-5 | Itraconazole | 200 | 4.3 | M1-2 |
| 4-6 | Voriconazole | 400 | 5.1 | M1-6 |
| 4-7 | Posaconazole | 100 | 4.9 | M1-5 |
| 4-8 | Caspofungin | 200 | 5.2 | M1-4 |
| 4-9 | MFG | 500 | 4.8 | M1-3 |
| 4-10 | Anidulafungin | 100 | 5.4 | M1-2 |
| 4-11 | Amphotericin B | 50 | 5.2 | M2-6 |
| 4-12 | Fluconazol | 100 | 4.9 | M2-5 |
| 4-13 | Ketoconazole | 200 | 5.8 | M2-4 |
| 4-14 | Miconazole nitrate | 200 | 5.3 | M2-3 |
| 4-15 | Itraconazole | 200 | 4.3 | M2-2 |
| 4-16 | Voriconazole | 400 | 5.1 | M2-6 |
| 4-17 | Posaconazole | 100 | 4.9 | M2-5 |
| 4-18 | Caspofungin | 200 | 5.2 | M2-4 |
| 4-19 | MFG | 500 | 4.8 | M2-3 |
| 4-20 | Anidulafungin | 100 | 5.4 | M2-2 |
| 4-21 | Amphotericin B | 50 | 5.2 | M3-6 |
| 4-22 | Fluconazol | 100 | 4.9 | M3-5 |
| 4-23 | Ketoconazole | 200 | 5.8 | M3-4 |
| 4-24 | Miconazole nitrate | 200 | 5.3 | M3-3 |
| 4-25 | Itraconazole | 200 | 4.3 | M3-2 |
| 4-26 | Voriconazole | 400 | 5.1 | M3-6 |
| 4-27 | Posaconazole | 100 | 4.9 | M3-5 |
| 4-28 | Caspofungin | 200 | 5.2 | M3-4 |
| 4-29 | MFG | 500 | 4.8 | M3-3 |
| 4-30 | Anidulafungin | 100 | 5.4 | M3-2 |
Embodiment 5
Active component 1 is dissolved in ethanol, after filtration, filtrate adopts spraying dry, D90 particle diameter sees the following form, inhalant adjuvant micronization, ratio of adjuvant, mean diameter see the following form, by active component 1,2 and adjuvant mixing, be dispensed in 1000 No. 3 capsules after crossing 3 mixings of 200 mesh sieve, the active component in every capsules sees the following form.
Process conditions are: inlet temperature is 100 DEG C, and outlet temperature is 68 DEG C, throughput 90%, and jet expansion internal diameter is 0.1cm, nozzle air flow velocity 800ml/min, sample introduction speed 30mL/h.
The explanation of matched group situation
The medicine composition of matched group 1-1 to 5-6 does not contain active component 1 compared with the Example formulations of corresponding group number, that is the one-tenth of matched group 1-1 to 5-6 is grouped into only containing the active component 2 in the embodiment of corresponding group number and excipient substance, proportioning, preparation technology is identical, such as embodiment 1-3 group is ketoconazole containing active component 1, active component 2 is M1-1 and pharmaceutic adjuvant, corresponding matched group 1-3 is then only containing active component 2(M1-1) and excipient substance, not containing active component 1, active component 2(M1-1) with the amount of excipient substance and the active component 2(M1-1 of embodiment 1-3 group) identical with the amount of excipient substance.
The preparation method of matched group 6-1 to 6-10:
According to following table by active component 1 fluid energy mill micronization, particle diameter is as following table, and Lactis Anhydrous 10g fluid energy mill is micronized to mean diameter 42 μm, after mixing, be divided in 1000 No. 3 capsules after crossing 3 mixings of 200 mesh sieve, the active component in every capsules sees the following form.
| Contrast group number | Active component 1 | Dosage (μ g/ grain) | D90 particle diameter (μm) |
| 6-1 | Amphotericin B | 50 | 5.2 |
| 6-2 | Fluconazol | 100 | 4.9 |
| 6-3 | Ketoconazole | 200 | 5.8 |
| 6-4 | Miconazole nitrate | 200 | 5.3 |
| 6-5 | Itraconazole | 200 | 4.3 |
| 6-6 | Voriconazole | 400 | 5.1 |
| 6-7 | Posaconazole | 100 | 4.9 |
| 6-8 | Caspofungin | 200 | 5.2 |
| 6-9 | MFG | 500 | 4.8 |
| 6-10 | Anidulafungin | 100 | 5.4 |
Pharmacological Examples 1 asthma pharmacological evaluation
1, animal model
Choose healthy male Wistar rat (there is antibacterial to checking out, the rat of fungal infection will not select), body weight is 200 ± 10g, put into the bell glass of about 5 liters, spray into 3% chlorination second phthalein choline and 0.1% histamine phosphate's volume mixed liquor 15 second with the pressure of 400mmHg.After spraying stops, observing the asthmatic latent period (namely asthma occur, breathe be the devil, until twitch time of falling) of rat, draw and breathe heavily the rat that the latent phase is less than 70 seconds or is greater than 120 seconds and will not select,
2, experimental technique
Learn from else's experience and measure the qualified rat of asthmatic latent period, random packet is carried out according to the group in following table, often organize 10, every day carries out administration in the bell glass of about 5 liters, experimental group gives the medicine in embodiment according to the arrangement inhalation route of following table, model group 1 gives according to inhalation route the Lactis Anhydrous that mean diameter is 55 μm, dosage is 5mg/Kg, matched group inhalation route gives corresponding dosage matched group medicine, observe after successive administration asthmatic latent period and tic incidence rate before and after drug change (draw animal when breathing heavily do not occur in 6 minutes the person of falling with draw breathe heavily the volt phase be 360 seconds calculate).
Dosage in experimental group, matched group 6-1 to 6-10 is all as the criterion with antifungal agent dosage, and the dosage of the active component 2 that the drug dose in matched group 1-1 to 5-6 gives according to corresponding experimental group gives.
3, experimentation and result: animal generation asthma until the time of falling of twitching see the following form.
Have multiple form to be the result of this experiment in the present embodiment, problem for convenience of explanation, splits experimental result.
Table 1-1 uses merely antifungal drug experimental result (n=10, mean ± SD)
Difference is not had afterwards before administration by the asthmatic latent period of T testing identity asthmatic model animal by above-mentioned experimental data, basically identical with not administration group, can illustrate that asthmatic model animal only gives antifungal drug, cannot Paroxysmal asthma be extended.
Table 1-2 contains the experimental result (n=10, mean ± SD) of tripartite's compound preparation of antifungal drug
Table 1-3 contains the experimental result (n=10, mean ± SD) of the cubic compound preparation of antifungal drug
Can be illustrated by T inspection by the experimental data showing 1-2,1-3, the curative effect of the tripartite containing antifungal drug or the composition for inhalation in four directions is much better than the composition for inhalation of antifungal drug folk prescription.
The experimental result (n=10, mean ± SD) of the compound preparation of table 1-4 not containing antifungal drug
By table 1-4 with show 1-3 group result of the test and to be checked by T and compare, prove that the curative effect of the tripartite after adding antifungal drug or cubic compound recipe Inhaled pharmaceutical composition exists larger difference with corresponding two sides not containing antifungal drug or tripartite's compound recipe Inhaled pharmaceutical composition, thus the curative effect that proof adds the tripartite after antifungal drug or cubic compound recipe Inhaled pharmaceutical composition is more excellent.
Pharmacological Examples 2 chronic obstructive pulmonary disease pharmacological evaluation
1, chronic obstructive pulmonary disease animal:
Male secondary SD rat, Mus age 8 week age, body weight 150 ~ 170g.Animal is adopted instillation Porcine trypsin method in fumigation (Golden Bridge) gas-adding pipe, namely the 1st, 15 day is tested through trachea instillation Porcine trypsin 0.5mg/kg, start smoked 5% medicated cigarette next day, 1 hour every morning, until the last day of the 10th week.
2, experimental technique
Get healthy male secondary SD rat 10, Mus age 8 week age, body weight 150 ~ 170g, is set to model group 2, and every day gives according to inhalation route the Lactis Anhydrous that mean diameter is 55 μm in the bell glass of about 5 liters, and dosage is 5mg/Kg, successive administration 14 days.
Get the rat of making Chronic obstructive pulmonary disease, random packet is carried out according to the group in following table, often organize 10, every day carries out administration in the bell glass of about 5 liters, experimental group gives the medicine in embodiment according to the arrangement inhalation route in following table, model group 1 gives according to inhalation route the Lactis Anhydrous that mean diameter is 55 μm, and dosage is 5mg/Kg, matched group inhalation route gives corresponding dosage matched group medicine, the equal successive administration of experimental group, model group 1, matched group 14 days.
Dosage in experimental group, matched group 6-1 to 6-10 is all as the criterion with antifungal agent dosage, and the dosage of the active component 2 that the drug dose in matched group 1-1 to 5-6 gives according to corresponding experimental group gives.
3, experimentation and result: experimental group, model group 1,2, rat was put to death in the 11st day after matched group administration, get the right lower lobe lung tissue of every rat, specimens paraffin embedding slices, carry out elastic fibers dyeing, carry out the mensuration of elastic fiber relative amount by HIPS-1000 multi-functional true color pathological picture and text analytical system, concrete data see the following form.
Have multiple form to be the result of this experiment in the present embodiment, problem for convenience of explanation, splits experimental result.
Table 2-1 uses merely antifungal drug experimental result (n=10, mean ± SD)
| Group | Medicine | Dosage every day (μ g/kg) | Elastic fiber relative amount (%) |
| Matched group 6-1 | Amphotericin B | 50 | 11.6±1.5 |
| Matched group 6-2 | Fluconazol | 100 | 11.9±1.4 |
| Matched group 6-3 | Ketoconazole | 200 | 11.7±1.6 |
| Matched group 6-4 | Miconazole nitrate | 200 | 11.8±1.5 |
| Matched group 6-5 | Itraconazole | 200 | 11.7±1.6 |
| Matched group 6-6 | Voriconazole | 400 | 11.9±1.6 |
| Matched group 6-7 | Posaconazole | 100 | 11.6±1.5 |
| Matched group 6-8 | Caspofungin | 200 | 11.8±1.6 |
| Matched group 6-9 | MFG | 500 | 11.7±1.5 |
| Matched group 6-10 | Anidulafungin | 100 | 11.5±1.4 |
| Model group 1 | Nothing | 11.6±1.5 | |
| Model group 2 | Nothing | 22.7±1.9 |
Difference is not had afterwards before administration by the elastic fiber relative amount of T testing identity Chronic obstructive pulmonary disease animal by above-mentioned experimental data, basically identical with not administration group, can illustrate that Chronic obstructive pulmonary disease animal only gives antifungal drug, the relative scale of lung fiber cannot be improved.
Table 2-2 contains the experimental result (n=10, mean ± SD) of tripartite's compound preparation of antifungal drug
| Group | Medicine | Dosage every day (μ g/kg) | Elastic fiber relative amount (%) |
| Model group 1 | Nothing | 11.6±1.5 | |
| Embodiment 1-1 | Amphotericin B | 50 | 15.8±1.6 |
| Embodiment 1-11 | Amphotericin B | 50 | 15.3±1.5 |
| Embodiment 1-21 | Amphotericin B | 50 | 15.4±1.6 |
| Embodiment 1-2 | Fluconazol | 100 | 16.6±1.9 |
| Embodiment 1-12 | Fluconazol | 100 | 16.3±1.6 |
| Embodiment 1-22 | Fluconazol | 100 | 16.4±1.8 |
| Embodiment 1-3 | Ketoconazole | 200 | 16.4±1.7 |
| Embodiment 1-13 | Ketoconazole | 200 | 16.1±1.7 |
| Embodiment 1-23 | Ketoconazole | 200 | 16.2±1.8 |
| Embodiment 1-5 | Itraconazole | 200 | 17.2±1.7 |
| Embodiment 1-15 | Itraconazole | 200 | 16.8±1.6 |
| Embodiment 1-25 | Itraconazole | 200 | 17.1±1.8 |
| Embodiment 1-6 | Voriconazole | 400 | 17.4±1.8 |
| Embodiment 1-16 | Voriconazole | 400 | 17.1±1.9 |
| Embodiment 1-26 | Voriconazole | 400 | 17.3±1.7 |
| Embodiment 1-7 | Posaconazole | 100 | 16.1±2.0 |
| Embodiment 1-17 | Posaconazole | 100 | 15.5±1.7 |
| Embodiment 1-27 | Posaconazole | 100 | 16.8±1.8 |
| Embodiment 1-8 | Caspofungin | 200 | 16.1±1.8 |
| Embodiment 1-18 | Caspofungin | 200 | 15.4±1.5 |
| Embodiment 1-28 | Caspofungin | 200 | 15.9±1.6 |
| Embodiment 1-10 | Anidulafungin | 100 | 15.9±1.6 |
| Embodiment 1-20 | Anidulafungin | 100 | 15.3±1.5 |
| Embodiment 1-30 | Anidulafungin | 100 | 15.7±1.7 |
Can be illustrated by T inspection by the experimental data showing 2-2, the curative effect of the composition for inhalation of the tripartite containing antifungal drug is much better than the composition for inhalation of antifungal drug folk prescription, the composition for inhalation in the same four directions due to antifungal drug adds a kind of medicine compared with all medicines of the composition for inhalation of tripartite, also can prove that the curative effect of the composition for inhalation in the four directions of antifungal drug is much better than the composition for inhalation of antifungal drug folk prescription.
The experimental result (n=10, mean ± SD) of the compound preparation of table 2-3 not containing antifungal drug
| Matched group number | Medicine | Elastic fiber relative amount (%) |
| 2-1 | M1-2 | 14.4±1.9 |
| 2-2 | M1-3 | 14.7±1.8 |
| 2-3 | M1-4 | 14.8±1.4 |
| 2-4 | M1-5 | 14.6±1.6 |
| 2-5 | M1-6 | 14.8±1.7 |
| 2-11 | M2-2 | 14.7±1.5 |
| 2-12 | M2-3 | 14.6±1.4 |
| 2-13 | M2-4 | 14.3±1.6 |
| 2-14 | M2-5 | 14.1±1.4 |
| 2-15 | M2-6 | 14.8±1.7 |
| 2-21 | M3-2 | 14.5±1.9 |
| 2-22 | M3-3 | 14.8±1.8 |
| 2-23 | M3-4 | 14.9±1.6 |
| 2-24 | M3-5 | 14.5±1.7 |
| 2-25 | M3-7 | 14.5±1.8 |
| 2-30 | M3-6 | 14.1±1.6 |
| 1-1 | M1-1 | 13.7±1.4 |
| 1-11 | M2-1 | 13.5±1.3 |
| 1-21 | M3-1 | 13.5±1.4 |
By table 2-3 with show 2-2 group result of the test and to be checked by T and compare, prove that the curative effect of the tripartite's compound recipe Inhaled pharmaceutical composition after adding antifungal drug and corresponding two side's compound recipe Inhaled pharmaceutical compositions not containing antifungal drug exist larger difference treating in chronic obstructive disease of lung, thus the curative effect that proof adds the tripartite after antifungal drug or cubic compound recipe Inhaled pharmaceutical composition is more excellent.
Claims (10)
1. one kind can suck compound medicament composition, it is characterized in that the pharmaceutic adjuvant being applicable to inhalation by one or more, and as the antifungal medicine of active component, the 2-3 kind composition in the 7 class medicines such as glucocorticoid, anticholinergic agent, LTRA, mastocyte membrane stabilizer, phosphodiesterase inhibitor, epinephrine broxaterol, H1 receptor antagonist.
2. pharmaceutical composition as claimed in claim 1, is characterized in that described antifungal medicine is one or more in polyenoid class, triazole type or echinocandin antifungal agent thing.
3. pharmaceutical composition as claimed in claim 13, it is characterized in that described polyene antifungal medicine is selected from nystatin, amphotericin B, methylpartricin, hachimycin, described antifungal drug in triazole class is selected from fluconazol, ketoconazole, miconazole, itraconazole, voriconazole, posaconazole; Described echinocandin antifungal agent thing is selected from Caspofungin, MFG, anidulafungin.
4. pharmaceutical composition as described in as arbitrary in claim 1-3, is characterized in that described pharmaceutical composition is powder spray or aerosol.
5. pharmaceutical composition as claimed in claim 4, is prepared into powder spray, it is characterized in that described pharmaceutic adjuvant comprises in carrier, additives one or more.
6. pharmaceutical composition as claimed in claim 5, is characterized in that the mean diameter of described carrier is 20 ~ 80 μm.
7. pharmaceutical composition as claimed in claim 5, is characterized in that described carrier is one or more in saccharide, aminoacid, lecithin, phosphatidylcholine.
8. pharmaceutical composition as described in as arbitrary in claim 5-7, it is characterized in that described powder spray, the summation of described active component and the weight ratio of carrier are 1:1 ~ 1000.
9. pharmaceutical composition as claimed in claim 4, is characterized in that described pharmaceutical composition, is prepared into aerosol, and described pharmaceutic adjuvant comprises the pharmaceutically useful propellant and other optional additives that are applicable to aerosol.
10. pharmaceutical composition as described in as arbitrary in claim 1-9 preparation treatment non-microorganism infect cause asthma, chronic obstructive pulmonary disease medicine in application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310205736.8A CN104208701A (en) | 2013-05-29 | 2013-05-29 | Compound inhalation preparation containing antifungal drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310205736.8A CN104208701A (en) | 2013-05-29 | 2013-05-29 | Compound inhalation preparation containing antifungal drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104208701A true CN104208701A (en) | 2014-12-17 |
Family
ID=52090872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310205736.8A Pending CN104208701A (en) | 2013-05-29 | 2013-05-29 | Compound inhalation preparation containing antifungal drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104208701A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3095755A1 (en) * | 2019-05-10 | 2020-11-13 | Balmes Transplantation | New cytoprotective drugs |
| CN114159474A (en) * | 2021-12-14 | 2022-03-11 | 雷允上药业集团有限公司 | Application of liushen pills in preparation of medicine for treating fungal pneumonia |
| CN115337311A (en) * | 2022-09-26 | 2022-11-15 | 南京恒道医药科技股份有限公司 | A composition for treating respiratory system diseases and its preparation method |
| CN118634190A (en) * | 2024-08-12 | 2024-09-13 | 上海方予健康医药科技有限公司 | A triazole drug suspension and its preparation method and use |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1282251A (en) * | 1997-10-22 | 2001-01-31 | 杰恩斯·庞尼阔 | Methods and materials for treating and preventing inflammation of mucosal tissue |
| US20070202133A1 (en) * | 1999-10-21 | 2007-08-30 | Sircar Jagadish C | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| CN101756942A (en) * | 2008-12-25 | 2010-06-30 | 天津金耀集团有限公司 | Oral lung inhalation aerosol powder |
-
2013
- 2013-05-29 CN CN201310205736.8A patent/CN104208701A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1282251A (en) * | 1997-10-22 | 2001-01-31 | 杰恩斯·庞尼阔 | Methods and materials for treating and preventing inflammation of mucosal tissue |
| US20070202133A1 (en) * | 1999-10-21 | 2007-08-30 | Sircar Jagadish C | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| CN101756942A (en) * | 2008-12-25 | 2010-06-30 | 天津金耀集团有限公司 | Oral lung inhalation aerosol powder |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3095755A1 (en) * | 2019-05-10 | 2020-11-13 | Balmes Transplantation | New cytoprotective drugs |
| WO2020229761A1 (en) * | 2019-05-10 | 2020-11-19 | Balmes Transplantation | Novel cytoprotective medicaments |
| CN114159474A (en) * | 2021-12-14 | 2022-03-11 | 雷允上药业集团有限公司 | Application of liushen pills in preparation of medicine for treating fungal pneumonia |
| CN114159474B (en) * | 2021-12-14 | 2024-05-17 | 雷允上药业集团有限公司 | Application of liushen pills in preparation of medicines for treating fungal pneumonia |
| CN115337311A (en) * | 2022-09-26 | 2022-11-15 | 南京恒道医药科技股份有限公司 | A composition for treating respiratory system diseases and its preparation method |
| CN115337311B (en) * | 2022-09-26 | 2023-05-09 | 南京恒道医药科技股份有限公司 | A composition for treating respiratory system diseases and its preparation method |
| CN118634190A (en) * | 2024-08-12 | 2024-09-13 | 上海方予健康医药科技有限公司 | A triazole drug suspension and its preparation method and use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101803121B1 (en) | Pharmaceutical formulation comprising a phosphodiesterase inhibitor | |
| US20230147683A1 (en) | Treatment | |
| JP2014516062A (en) | Combinations containing umecridinium and corticosteroids | |
| TW200524615A (en) | Aqueous suspensions of ciclesonide for nebulisation | |
| UA119773C2 (en) | Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd | |
| CN104208701A (en) | Compound inhalation preparation containing antifungal drug | |
| KR20230038228A (en) | glucocorticoid sparing agent | |
| TWI449523B (en) | Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate | |
| ES2661090T3 (en) | An inhalable medicine | |
| EA035740B1 (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| EA015353B1 (en) | Use of tiotropium salts in the treatment of moderate persistent asthma | |
| WO2013026269A1 (en) | Method for preparing metered dose sprayed inhaler for treating respiratory disease | |
| ITMI20130571A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING BUDESONIDE AND FORMOTEROL | |
| CN104208045A (en) | Compound inhalation preparation containing penicillin antibiotic and glucocorticoid | |
| RU2519653C1 (en) | Aerosol preparation of ipratropium bromide for treating respiratory diseases | |
| CN103830208A (en) | H1-receptor-antagonist-containing inhalation preparation | |
| CN104208687A (en) | Dry powder inhalation pharmaceutical composition containing different active components packaged in inhalation device for synchronous application | |
| CN104208688A (en) | Pharmaceutical composition containing individually-packaged mometasone furoate and epinephrine beta2-acceptor stimulant placed in inhalation device for synchronous application | |
| CN104208690A (en) | Pharmaceutical composition containing individually-packaged ciclesonide and epinephrine beta2-acceptor stimulant placed in inhalation device for synchronous application | |
| CN104208060A (en) | Compound inhalation preparation containing penicillin antibiotic | |
| CN104208700A (en) | Compound inhalation preparation containing antibacterial drug | |
| CN104208689A (en) | Pharmaceutical composition containing individually-packaged budesonide and epinephrine beta2-acceptor stimulant placed in inhalation device for synchronous application | |
| CN104208686A (en) | Pharmaceutical composition containing individually-packaged fluticasone and epinephrine beta2-acceptor stimulant placed in inhalation device for synchronous application | |
| US10653704B2 (en) | Inhalable formulation | |
| CN114796166A (en) | Aerosol containing terpene volatile oil and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20141217 |
|
| WD01 | Invention patent application deemed withdrawn after publication |